Company Profile
Karyopharm Therapeutics Stock Price, News & Analysis
- Ticker:
- KPTI
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Karyopharm Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
9.65 USD (+7.22%)
Close
Last updated: June 23, 2026 at 00:00
218.7M USD
Market cap
Why the stock is moving
KPTI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Karyopharm Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Karyopharm Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Karyopharm Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
Source: Karyopharm Therapeutics
- 02
- 03
- 04
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: Karyopharm Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Karyopharm Therapeutics (KPTI)?
Karyopharm Therapeutics (KPTI) most recently closed at 9.65 USD, a +7.22% move versus the previous session.
What is the market cap of Karyopharm Therapeutics (KPTI)?
Karyopharm Therapeutics currently has a market capitalization of 218.7M USD on BioPharmSignal.
What does Karyopharm Therapeutics do?
Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is KPTI stock listed?
Karyopharm Therapeutics (KPTI) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Karyopharm Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Karyopharm?
Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Karyopharm Therapeutics targeting with Karyopharm?
Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.